Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
The firm will submit a rolling NDA to the agency in early 2027, containing data from the randomized, controlled EMPEROR trial.
The T2EVOLVE association cements the work of a temporary Innovative Medicines Initiative-funded project that began in 2021.
The firm is preparing to test a gene replacement therapy that uses an ultrasound-mediated strategy to deliver a full-length ...
The agency expects to issue decisions on Vyondys 53 and Amondys 45, which missed their primary endpoint in a confirmatory trial, by February 2027.
The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
Innovent Biologics will commercialize Eli Lilly's CDK4/6 inhibitor Verzenio (abemaciclib) in mainland China, where it is called Verzenios, the companies announced Tuesday. Lilly will retain rights to ...
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
The acquisition will bring navtemadlin, Kartos' late-stage treatment program in myelofibrosis, to Ipsen's pipeline.
The firm also said it completed enrollment in the Phase III 4FRONT-2 clinical trial of 4D-150 in wet AMD ahead of schedule.
The European Commission on Monday approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as a tissue-agnostic treatment for previously treated patients with unresectable or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results